top of page

Boustead Client Know Labs, Inc. (NYSE: KNW) Recognized by the Wall Street Journal for their Developments in Non-Invasive Blood Glucose Monitoring Solutions

Irvine, CA — January 8, 2024 – Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (NYSE: KNW), an emerging developer of non-invasive medical diagnostic technology, was recognized by the Wall Street Journal's article 'Apple Keeps Chasing the Ultimate Health-Tracking Watch—but It Could Take Years'. 

 

"The Wall Street Journal has reported that Apple is planning to enhance its watches with health features in the coming years, including working on ways of measuring blood pressure, glucose levels, body temperature and other health metrics. Its cautious approach means it sometimes rolls out features slower than competitors.

 

Other companies—including the startups Know Labs in Seattle and Hagar in Tel Aviv—are also working on methods for tracking blood sugar without puncturing the skin. In 2014, Google launched a project to track glucose with an electronic contact lens, but abandoned it four years later because of challenges in achieving reliable readings."

 

To learn more about Know Labs proprietary non-invasive diagnostic technology, click here.

 

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a glucose monitor. It will provide the user with real time information on their blood glucose levels. This product will require US Food and Drug Administration approval prior to its introduction to the market.


Boustead Securities, LLC

Boustead Securities, LLC is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority-owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information visit please visit: www.boustead1828.com

0 views0 comments

Recent Posts

See All

Comments


bottom of page